Simulations Plus, Inc.

NASDAQ:SLP

Medical - Healthcare Information Services

Healthcare
$18.50 +0.11%

+$0.02 today

Market cap
$374.16M
Beta
1.32
P/E (TTM)
-5.9
EPS (TTM)
-$3.12
52W Low $11.09High $21.01

Volume 0.00M

Average 0.35M

SLP Debt Repayment

Cash used to repay borrowings during the period.

Simulations Plus, Inc.NASDAQ: SLP

Debt Repayment · Q2 FY2026 · quarter ended Feb 2026

Debt repayment outflow grows to $0

Q2 FY2026 debt repayment was $0, compared with $0 a year earlier. Trailing-twelve-month debt repayment was $0.

Context

  • Debt repayment amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Debt repayment increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterFeb 2026
$0— QoQ
Last fiscal yearAug 2025
$0— YoY
LTMFeb 2026
$0— YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Debt Repayment vs competitors

How SLP compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Debt repayment amounts to 0.0% of revenue for SLP, versus a peer median of 9.2%.
SLP Competitors
Debt Repayment for SLP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NAKANakamoto Inc.LTM Mar 2026$191.29M USD+28024.8%+984.3%4880.4%
NRCNational Research CorporationLTM Mar 2026$12.7M USD-45.1%—9.2%
CLLSCellectis S.A.LTM Mar 2026$10.97M USD+77.8%-6.5%16.1%
OPRXOptimizeRx CorporationLTM Mar 2026$10.19M USD+154.8%—9.5%
DHDefinitive Healthcare Corp.LTM Mar 2026$8.75M USD-89.3%+126.1%3.7%
AGLAgilon Health, Inc.LTM Mar 2026$3.5M USD+40.0%—0.1%
SOPHSOPHiA GENETICS S.A.LTM Mar 2026$1.98M USD-20.2%—2.4%
ACIUAC Immune S.A.LTM Dec 2025CHF 1.03M CHF+50.2%+21.7%28.7%
ANROAlto Neuroscience, Inc.LTM Mar 2026$750K USD-93.0%-1.2%—
SLPSimulations Plus, Inc.LTM Feb 2026$0 USD——0.0%
KRROKorro Bio, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding SLP) —+40.0%+21.7%9.2%

Competitors are the stored peer set for SLP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Aug 2021
FY2022
Aug 2022
FY2023
Aug 2023
FY2024
Aug 2024
FY2025
Aug 2025
Net Income9.78M12.48M9.96M9.95M(64.72M)
Depreciation & Amortization3.59M3.57M3.84M5.67M8.21M
Deferred Income Tax(628K)(270K)(2.1M)(1.77M)(5.43M)
Stock-Based Compensation2.75M3.04M4.83M6.54M6.35M
Change in Working Capital974K(2.62M)5.1M(4.21M)(2.59M)
Accounts Receivables(2.43M)(3.94M)4.1M3.13M(581K)
Inventory3.15M0000
Accounts Payables39K(162K)(81K)(477K)(132K)
Other Working Capital210K1.48M1.09M(6.86M)(1.87M)
Other Non-Cash Items2.74M1.7M219K(2.86M)76.29M
Operating Cash Flow19.2M17.9M21.86M13.32M18.13M
Capital Expenditures(4.58M)(3.97M)(4.27M)(566K)(713K)
Acquisitions (Net)2.95M3.15M(8.22M)(98.77M)0
Purchases of Investments(122.4M)(100.85M)(95.05M)(67.16M)(6.5M)
Sales of Investments100.23M109.12M114.91M116.27M15.01M
Other Investing Activities(2.95M)(3.15M)(3.82M)(3.74M)(4.24M)
Investing Cash Flow(26.74M)4.31M7.37M(53.97M)3.56M
Debt Repayment00000
Common Stock Issued1.46M891K0731K430K
Common Stock Repurchased00(20M)00
Dividends Paid(4.81M)(4.85M)(4.81M)(4.8M)0
Other Financing Activities(1.33M)(3.67M)1.54M(2.5M)(1.58M)
Financing Cash Flow(4.68M)(7.62M)(23.27M)(6.57M)(1.15M)
Effect of Forex Changes00000
Net Change in Cash(12.22M)14.58M5.96M(47.21M)20.54M
Free Cash Flow14.63M13.93M17.58M12.75M17.41M

Simulations Plus, Inc.

NASDAQ:SLP

Intrinsic Alpha fair value

Locked

Current Price

$18.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.